Heideman, D.A.M.; Oštrbenk Valenčak, A.; Doorn, S.; Bonde, J.; Hillemanns, P.; Gimpelj Domjanič, G.; Mlakar, J.; Hesselink, A.T.; Meijer, C.J.L.M.; Poljak, M.
Clinical Validation of the Fully Automated NeuMoDx HPV Assay for Cervical Cancer Screening. Viruses 2022, 14, 893.
https://doi.org/10.3390/v14050893
AMA Style
Heideman DAM, Oštrbenk Valenčak A, Doorn S, Bonde J, Hillemanns P, Gimpelj Domjanič G, Mlakar J, Hesselink AT, Meijer CJLM, Poljak M.
Clinical Validation of the Fully Automated NeuMoDx HPV Assay for Cervical Cancer Screening. Viruses. 2022; 14(5):893.
https://doi.org/10.3390/v14050893
Chicago/Turabian Style
Heideman, Daniëlle A. M., Anja Oštrbenk Valenčak, Saskia Doorn, Jesper Bonde, Peter Hillemanns, Grega Gimpelj Domjanič, Jana Mlakar, Albertus T. Hesselink, Chris J. L. M. Meijer, and Mario Poljak.
2022. "Clinical Validation of the Fully Automated NeuMoDx HPV Assay for Cervical Cancer Screening" Viruses 14, no. 5: 893.
https://doi.org/10.3390/v14050893
APA Style
Heideman, D. A. M., Oštrbenk Valenčak, A., Doorn, S., Bonde, J., Hillemanns, P., Gimpelj Domjanič, G., Mlakar, J., Hesselink, A. T., Meijer, C. J. L. M., & Poljak, M.
(2022). Clinical Validation of the Fully Automated NeuMoDx HPV Assay for Cervical Cancer Screening. Viruses, 14(5), 893.
https://doi.org/10.3390/v14050893